Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Gross Profit (2023 - 2025)

Fennec Pharmaceuticals' Gross Profit history spans 3 years, with the latest figure at $7.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 92.69% year-over-year to $7.7 million, compared with a TTM value of $32.0 million through Dec 2025, down 13.59%, and an annual FY2025 reading of $26.0 million, down 10.6% over the prior year.
  • Gross Profit for Q4 2025 was $7.7 million at Fennec Pharmaceuticals, up from $7.3 million in the prior quarter.
  • The five-year high for Gross Profit was $24.8 million in Q1 2024, with the low at $1.6 million in Q1 2023.
  • Average Gross Profit over 3 years is $7.4 million, with a median of $6.7 million recorded in 2023.
  • Year-over-year, Gross Profit skyrocketed 1469.34% in 2024 and then crashed 66.25% in 2025.
  • Tracing FENC's Gross Profit over 3 years: stood at $9.0 million in 2023, then tumbled by 56.01% to $4.0 million in 2024, then skyrocketed by 92.69% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for FENC's Gross Profit are $7.7 million (Q4 2025), $7.3 million (Q3 2025), and $8.7 million (Q2 2025).